

# Harold L Atkins

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5347879/harold-l-atkins-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

67  
papers

1,607  
citations

22  
h-index

39  
g-index

82  
ext. papers

1,973  
ext. citations

7  
avg, IF

4.41  
L-index

#	Paper	IF	Citations
67	Mesenchymal stem cell therapy and cognition in MS: Preliminary findings from a phase II clinical trial.. <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 61, 103779	4	0
66	Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis, the Ottawa Protocol.. <i>Current Protocols</i> , <b>2022</b> , 2, e437		
65	Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation - a retrospective analysis. <i>Hematology, Transfusion and Cell Therapy</i> , <b>2021</b> , 43, 437-442	1.6	
64	Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 167-173	5	1
63	Hematologists' barriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview study. <i>Trials</i> , <b>2021</b> , 22, 230	2.8	3
62	Navigating choice in the face of uncertainty: using a theory informed qualitative approach to identifying potential patient barriers and enablers to participating in an early phase chimeric antigen receptor T (CAR-T) cell therapy trial. <i>BMJ Open</i> , <b>2021</b> , 11, e043929	3	2
61	Autologous Hematopoietic Stem Cell Transplantation for Chronic Inflammatory Demyelinating Polyradiculoneuropathy. <i>Canadian Journal of Neurological Sciences</i> , <b>2021</b> , 1-7	1	0
60	Personalized oncology and BRAF melanoma: model development, drug discovery, and clinical correlation. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2021</b> , 147, 1365-1378	4.9	0
59	A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 52, 102945	4	4
58	Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy. <i>BMJ Open</i> , <b>2021</b> , 11, e046707	3	0
57	Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis. <i>Systematic Reviews</i> , <b>2021</b> , 10, 35	3	4
56	Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trials. <i>Research Involvement and Engagement</i> , <b>2020</b> , 6, 61	4.4	3
55	Does Lymphocyte Count Impact Dosing of Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplantation?. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1298-1302	4.7	6
54	Total body irradiation (18 Gy) without chemotherapy as conditioning for allogeneic hematopoietic cell transplantation in refractory acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1454-1456	4.4	1
53	Importance of the hematology laboratory in infectious disease diagnosis by morphology: Four educational case studies. <i>International Journal of Laboratory Hematology</i> , <b>2020</b> , 42 Suppl 1, 133-137	2.5	
52	Building Canadian capacity for CAR-T cells in relapsed/refractory acute lymphoblastic leukaemia: a retrospective cohort study. <i>British Journal of Haematology</i> , <b>2020</b> , 191, e14-e19	4.5	1
51	Does Resetting the Immune System Fix Multiple Sclerosis?. <i>Canadian Journal of Neurological Sciences</i> , <b>2020</b> , 47, 1-10	1	4

50	Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , <b>2020</b> , 7, 767-775	5.3	10
49	Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 845-854	4.7	46
48	The impact of multiple myeloma induction therapy on hematopoietic stem cell mobilization and collection: 25-year experience. <i>Hematology, Transfusion and Cell Therapy</i> , <b>2019</b> , 41, 285-291	1.6	2
47	Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less. <i>Blood</i> , <b>2019</b> , 134, 3263-3263	2.2	
46	Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. <i>Transfusion Medicine Reviews</i> , <b>2019</b> , 33, 98-110	7.4	66
45	High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2019</b> , 6, e598	9.1	26
44	Autologous hematopoietic stem cell transplantation improves fatigue in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 1764-1772	5	9
43	Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Sclerosis. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2019</b> , 9,	5.4	13
42	Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 1055-1066	5	6
41	Effect of Donor Age and Donor Relatedness on Time to Allogeneic Hematopoietic Cell Transplantation in Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 2466-2470	4.7	5
40	Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 834	8.4	28
39	Complications and Toxicities Associated with Autologous Stem Cell Transplantation for Severe Autoimmune Diseases: Single Center Experience. <i>Blood</i> , <b>2018</b> , 132, 4624-4624	2.2	
38	Building Capacity for Relapsed/Refractory ALL Patients Needing CAR-T Cells: How Do We Prepare?. <i>Blood</i> , <b>2018</b> , 132, 5159-5159	2.2	
37	The stem cell market and policy options: a call for clarity. <i>Journal of Law and the Biosciences</i> , <b>2018</b> , 5, 743-758	4.1	8
36	Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 420-431	5	22
35	Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. <i>JAMA Neurology</i> , <b>2017</b> , 74, 459-469	17.2	147
34	Responsible Translation of Stem Cell Research: An Assessment of Clinical Trial Registration and Publications. <i>Stem Cell Reports</i> , <b>2017</b> , 8, 1190-1201	8	46
33	Autoimmune disorders <b>2017</b> , 221-228		

32	Immunoablation and aHSCT for aggressive multiple sclerosis - AuthorsTreply. <i>Lancet, The</i> , <b>2017</b> , 389, 908	4.0	1
31	Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 2096-2101	4.7	22
30	Five Questions Answered: A Review of Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis. <i>Neurotherapeutics</i> , <b>2017</b> , 14, 888-893	6.4	12
29	Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , <b>2017</b> , 7, e019321	3	14
28	Cell-based therapeutic strategies for multiple sclerosis. <i>Brain</i> , <b>2017</b> , 140, 2776-2796	11.2	102
27	Haematopoietic stem cell transplants should be a second-line therapy for highly active MS - YES. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1258-9	5	4
26	Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. <i>Lancet, The</i> , <b>2016</b> , 388, 576-85	4.0	234
25	Factors Influencing Long-Term Hematopoietic Function Following Autologous Stem Cell Transplantation. <i>Blood</i> , <b>2016</b> , 128, 2186-2186	2.2	
24	A Comparison of Cyclophosphamide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 4519-4519	2.2	0
23	Low-Dose Anti-Thymocyte Globulin for Graft-Versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , <b>2016</b> , 128, 5782-5782	2.2	0
22	One Size Fits All?: Ethical Considerations for Examining Efficacy in First-in-Human Pluripotent Stem Cell Studies. <i>Molecular Therapy</i> , <b>2016</b> , 24, 2039-2042	11.7	3
21	Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation. <i>JAMA Neurology</i> , <b>2016</b> , 73, 652-8	17.2	46
20	The ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implications. <i>Oncolytic Virotherapy</i> , <b>2015</b> , 4, 13-23	6	1
19	VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. <i>Cancer Cell</i> , <b>2015</b> , 28, 210-24	24.3	62
18	Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. <i>Nature Communications</i> , <b>2015</b> , 6, 6410	17.4	36
17	Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques. <i>Molecular Therapy</i> , <b>2015</b> , 23, 1066-1076	11.7	54
16	Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. <i>Nature Medicine</i> , <b>2015</b> , 21, 530-6	50.5	93
15	Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. <i>Regenerative Medicine</i> , <b>2015</b> , 10, 897-911	2.5	36

14	Granulocyte colony-stimulating factor therapy for stem cell mobilization following anterior wall myocardial infarction: the CAPITAL STEM MI randomized trial. <i>Cmaj</i> , <b>2014</b> , 186, E427-34	3.5	5
13	Autologous stem cell transplantation for stiff person syndrome: two cases from the Ottawa blood and marrow transplant program. <i>JAMA Neurology</i> , <b>2014</b> , 71, 1296-9	17.2	17
12	Cognitive fatigue in individuals with multiple sclerosis undergoing immunoablative therapy and hematopoietic stem cell transplantation. <i>Journal of the Neurological Sciences</i> , <b>2014</b> , 336, 132-7	3.2	9
11	Cognitive change and neuroimaging following immunoablative therapy and hematopoietic stem cell transplantation in multiple sclerosis: A pilot study. <i>Multiple Sclerosis and Related Disorders</i> , <b>2014</b> , 3, 129-35	4	4
10	Autologous Stem Cell Transplant for Myasthenia Gravis: A Single-Centre Experience. <i>Blood</i> , <b>2014</b> , 124, 3996-3996	2.2	2
9	Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned. <i>Neurotherapeutics</i> , <b>2013</b> , 10, 68-76	6.4	59
8	Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. <i>Annals of Neurology</i> , <b>2013</b> , 73, 341-54	9.4	105
7	Autologous hematopoietic stem cell transplantation for autoimmune disease--is it now ready for prime time?. <i>Biology of Blood and Marrow Transplantation</i> , <b>2012</b> , 18, S177-83	4.7	26
6	Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , <b>2012</b> , 18, 1471-8	4.7	47
5	Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. <i>Biology of Blood and Marrow Transplantation</i> , <b>2010</b> , 16, 1076-83	4.7	32
4	Immune ablation followed by autologous hematopoietic stem cell transplantation for the treatment of poor prognosis multiple sclerosis. <i>Methods in Molecular Biology</i> , <b>2009</b> , 549, 231-46	1.4	33
3	Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2008</b> , 14, 1039-1044	4.7	45
2	Immunoablative therapy as a treatment aggressive multiple sclerosis. <i>Neurologic Clinics</i> , <b>2005</b> , 23, 273-300, ix	4.5	15
1	A Randomized Trial Comparing the Effectiveness of Peripheral Blood Stem Cell Mobilization with Chemotherapy and Early vs Delayed Initiation of Granulocyte Colony-Stimulating Factor (G-CSF) in Patients with Lymphoma and Multiple Myeloma.. <i>Blood</i> , <b>2005</b> , 106, 2929-2929	2.2	